

# Atypical pneumonia: Unconventional pathogens and clinical manifestations.

Gail J DiNubile\*

Merck Research Laboratories, West Point, PA, USA

## Introduction

Atypical pneumonia refers to a specific subset of pneumonia cases caused by unconventional pathogens, including *Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*, *Legionella pneumophila*, and respiratory viruses. These pathogens differ from typical bacterial causes of pneumonia and often present with milder symptoms, leading to the term "walking pneumonia." However, despite the less severe presentation, atypical pneumonia can still result in significant morbidity if not promptly recognized and treated [1].

**Mycoplasma pneumoniae:** *Mycoplasma pneumoniae* is a common cause of atypical pneumonia, especially in young adults and school-aged children. It often presents with a gradual onset of symptoms, including persistent cough, sore throat, and malaise. **Chlamydomphila pneumoniae:** *Chlamydomphila pneumoniae* is another common pathogen associated with atypical pneumonia. It shares similarities in clinical presentation with *Mycoplasma pneumoniae*, with symptoms including cough, headache, and low-grade fever [2].

**Legionella pneumophila:** *Legionella pneumophila* is responsible for severe cases of atypical pneumonia, known as Legionnaires' disease. It is often associated with water sources and can cause severe respiratory symptoms, high fever, and multiorgan involvement. **Respiratory Viruses:** Certain respiratory viruses, such as influenza, respiratory syncytial virus (RSV), and adenovirus, can also cause atypical pneumonia. These viral infections may present with cough, fever, and respiratory distress [3].

Atypical pneumonia often presents with a more indolent course compared to typical bacterial pneumonia. Common symptoms include persistent cough, sore throat, headache, and fatigue. However, the absence of classic symptoms, such as high fever and productive cough, can make the diagnosis challenging. Clinical suspicion and specific diagnostic tests, such as serology and polymerase chain reaction (PCR), play a crucial role in identifying the causative pathogens [4].

Treatment of atypical pneumonia typically involves the use of appropriate antibiotics based on the suspected pathogens.

Macrolide antibiotics, such as azithromycin or clarithromycin, are commonly prescribed due to their efficacy against *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*. *Legionella pneumoniae* requires specific antibiotic regimens, such as fluoroquinolones or macrolides. Supportive care, including rest, adequate hydration, and antipyretics, is also important for symptom relief and recovery [5].

## Conclusion

Atypical pneumonia caused by unconventional pathogens poses unique diagnostic and management challenges. The diverse clinical manifestations and less severe presentation make timely recognition and appropriate treatment crucial for optimal patient outcomes. Increased awareness among healthcare professionals and utilization of specific diagnostic tests are necessary for accurate diagnosis and targeted therapy. Further research is needed to enhance our understanding of these unconventional pathogens and improve strategies for the prevention and management of atypical pneumonia.

## Reference

1. Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev.* 2004;17(4):697-728.
2. Jing C, Zhang X, Song Z, et al. Progranulin mediates proinflammatory responses in systemic lupus erythematosus: implications for the pathogenesis of systemic lupus erythematosus. *JICR.* 2020;40(1):33-42.
3. Leiman PG, Battisti AJ, Bowman VD, et al. The structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide capsules and evolution of new host specificities. *JMB.* 2007;371(3):836-49.
4. Prokhorov NS, Riccio C, Zdorovenko EL, et al. Function of bacteriophage G7C esterase tailspike in host cell adsorption. *Mol Microbiol.* 2017;105(3):385-98.
5. Plattner M, Shneider MM, Arbatsky NP, et al. Structure and function of the branched receptor-binding complex of bacteriophage CBA120. *J Mol Biol.* 2019;431(19):3718-39.

---

\*Correspondence to: Gail J DiNubile, Merck Research Laboratories, West Point, PA, USA. E-mail: [gail\\_dinubile@merck.com](mailto:gail_dinubile@merck.com)

Received: 30-May-2023, Manuscript No. AARRP-23-103832; Editor assigned: 01-June-2023, PreQC No. AARRP-23-103832(PQ); Reviewed: 15-June-2023, QC No. AARRP-23-103832; Revised: 20-June-2023, Manuscript No. AARRP-23-103832(R); Published: 27-June-2023, DOI: 10.35841/aarrp-4.3.143